Immunai Revenue and Competitors
Estimated Revenue & Valuation
- Immunai's estimated annual revenue is currently $50.6M per year.
- Immunai's estimated revenue per employee is $236,303
- Immunai's total funding is $295M.
Employee Data
- Immunai has 214 Employees.
- Immunai grew their employee count by 5% last year.
Immunai's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Staff | Reveal Email/Phone |
3 | VP, Corporate Development | Reveal Email/Phone |
4 | VP Product Management | Reveal Email/Phone |
5 | VP, Single Cell Immunology | Reveal Email/Phone |
6 | VP Human Resources | Reveal Email/Phone |
7 | Director, Molecular Profiling | Reveal Email/Phone |
8 | Director | Reveal Email/Phone |
9 | Senior Director, Collaborations | Reveal Email/Phone |
10 | Associate Director, Lab Operations | Reveal Email/Phone |
Immunai Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | 0% | N/A | N/A |
#2 | $3.7M | 24 | 41% | $44M | N/A |
#3 | $6.2M | 40 | -7% | N/A | N/A |
#4 | $42M | 271 | -1% | N/A | N/A |
#5 | $12.7M | 82 | 0% | $10M | N/A |
#6 | $2.5M | 16 | 0% | N/A | N/A |
#7 | $7.5M | 45 | 0% | $51.6M | N/A |
#8 | $0.2M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 26 | -16% | $3.3M | N/A |
#10 | $3.7M | 24 | 4% | N/A | N/A |
What Is Immunai?
Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
keywords:N/A
$295M
Total Funding
214
Number of Employees
$50.6M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Immunai News
Why Luis and his co-founder, two machine learning engineers, decided to start a bio startup. · How Immunai uses single-cell genomics to map out...
Immunai was founded in December 2018. We are a multidisciplinary team of immunologists, genomics technologists, computer scientists, engineers, mathematicians...
Immunai, a New York-based biotech startup, has raised USD 125 million in a Series B funding round led by Koch Disruptive Technologies on 27 October 2021. Investor: Koch Disruptive Technologies led the latest funding round with participation from Talos VC, 8VC, Alexandria Venture Investments, Pi ...
Israeli-founded biotech startup Immunai announced this week that it has raised a USD 215 million Series B round for its drug discovery platform, led by Koch Disruptive Technologies, with participation from Talos VC, 8VC, Alexandria Venture Investments, Piedmont, ICON, and previous investors. Th ...
Immunai, a New York-based biotech company, raised $215M in Series B funding, increasing the company’s total funding to date to $295M. The Series B was led by Koch Disruptive Technologies, with participation from Talos VC, 8VC, Alexandria Venture Investments, Piedmont, ICON, and more, including ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $32.2M | 214 | -14% | $144.7M |
#2 | $52.5M | 214 | 20% | $20.7M |
#3 | $34.1M | 214 | -16% | N/A |
#4 | $23.5M | 214 | 20% | N/A |
#5 | $7.5M | 214 | 91% | N/A |